Surgical Site Infection Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight's, "Surgical Site Infection Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Surgical Site Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Surgical Site Infection Research. Learn more about our innovative pipeline today! @ Surgical Site Infection Pipeline Outlook- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Surgical Site Infection Pipeline Report
• In November 2025- Ondine Biomedical Inc. announced a a Phase 3 multi-center, group-randomized, crossover trial to compare nasal antimicrobial photodisinfection therapy (aPDT) with standard of care for prevention of surgical site infections in patients undergoing major elective, urgent, or emergent surgeries in a hospital setting.
• In November 2025- University of Michigan conducted a studying a device already approved by the Food and Drug Administration (FDA) to treat wound closures. Researchers are studying a large group of people to continue to learn information about the safety of the STRATAFIX suture and how people's bodies react to using it over a long period of time. This research will provide additional information about using STRATAFIX sutures to close surgical wounds.
• DelveInsight's Surgical Site Infection pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Surgical Site Infection treatment.
• The leading Surgical Site Infection Companies such as Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and others.
• Promising Surgical Site Infection Therapies such as Ciprodiazole, IMP, D-PLEX, PLASOMA, Dupilumab, and others.

Stay informed about the cutting-edge advancements in Surgical Site Infection treatments. Download for updates and be a part of the revolution in care @ Surgical Site Infection Clinical Trials Assessment- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Surgical Site Infection Emerging Drugs Profile
• XF-73: Destiny Pharma plc
XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 has confirmed bactericidal activity. It is designated by the International Non-proprietary Name (INN) of exeporfinium chloride by the World Healthcare Organisation (WHO). XF-73 has been tested in vitro against a range of clinically important S. aureus isolates. It is active against methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA and vancomycin-intermediate S. aureus (VISA).

• D-PLEX100: POLYPID
PLEX (Polymer-Lipid Encapsulation matriX) platform is made of alternating layers of polymers and lipids that entrap a therapeutic drug to form a protected reservoir. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months, a rare combination of attributes. The novel D-PLEX100 product candidate delivers a broad-spectrum antibiotic, doxycycline, generating high local concentration over four weeks with minimal systemic exposure

Learn more about Surgical Site Infection Drugs opportunities in our groundbreaking Surgical Site Infection Research and development projects @ Surgical Site Infection Unmet Needs- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Surgical Site Infection Companies
Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and others.

Surgical Site Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Surgical Site Infection Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Discover the latest advancements in Surgical Site Infection treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Surgical Site Infection Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Surgical Site Infection Pipeline Report
• Coverage- Global
• Surgical Site Infection Companies- Destiny Pharma plc, POLYPID, Exoxemis, Covira Surgical, Inc., Eupraxia Pharmaceuticals, Sonoran Biosciences, and others.
• Surgical Site Infection Therapies- Ciprodiazole, IMP, D-PLEX, PLASOMA, Dupilumab, and others.
• Surgical Site Infection Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Surgical Site Infection Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Surgical Site Infection Pipeline on our website @ Surgical Site Infection Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Surgical Site Infection: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Surgical Site Infection - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. D-PLEX100: POLYPID
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. XF-73: Destiny Pharma plc
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. F573: Beijing Continent Pharmaceutical
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. EP-201: Eupraxia Pharmaceuticals
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Surgical Site Infection Key Companies
21. Surgical Site Infection Key Products
22. Surgical Site Infection- Unmet Needs
23. Surgical Site Infection- Market Drivers and Barriers
24. Surgical Site Infection- Future Perspectives and Conclusion
25. Surgical Site Infection Analyst Views
26. Surgical Site Infection Key Companies
27. Appendix

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and pharma sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.